ClearPoint Neuro shares are trading higher after the company reported better-than-expected Q4 financial results and reaffirmed FY24 revenue guidance. Also, Stifel reiterated a Buy rating on the stock and raised its price target from $8 to $9.
Benzinga Newsdesk - Mar 13, 2024, 1:40PM